Clinical data | |
---|---|
Trade names | Detectnet |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C65H88CuN14O19S2 |
Molar mass | 1497.16 g·mol−1 |
3D model (JSmol) | |
| |
|
Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.[2]
Common side effects include nausea, vomiting and flushing.[3]
It was approved for medical use in the United States in September 2020.[2][3]
The U.S. Food and Drug Administration (FDA) approved copper 64Cu dotatate based on data from two trials that evaluated 175 adults.[4]
Trial 1 evaluated adults, some of whom had known or suspected NETs and some of whom were healthy volunteers.[4] The trial was conducted at one site in the United States (Houston, TX).[4] Both groups received copper 64Cu dotatate and underwent PET scan imaging.[4]
Trial 2 data came from the literature-reported trial of 112 adults, all of whom had history of NETs and underwent PET scan imaging with copper 64Cu dotatate.[4] The trial was conducted at one site in Denmark.[4] In both trials, copper 64Cu dotatate images were compared to either biopsy results or other images taken by different techniques to detect the sites of a tumor.[4] The images were read as either positive or negative for presence of NETs by three independent image readers who did not know participant clinical information.[4]
Original source: https://en.wikipedia.org/wiki/Copper (64Cu) oxodotreotide.
Read more |